PRME

Prime Medicine Stock Analysis

AI Rating

Low
  • Quality1/10
  • Growth↓ 4/10
  • Value↓ 0/10
Prime Medicine sales and earnings growth
PRME Growth
Neutral
  • Revenue Y/Y↑ 55.28%
  • EPS Y/Y↑ 18.18%
  • FCF Y/Y↓ -28.38%
Prime Medicine gross and profit margin trends
PRME Profitability
Fair
  • Gross margin ↑ 100.00%
  • EPS margin↓ -4342.40%
  • ROIC 5Y↓ -102.18%
Prime Medicine net debt vs free cash flow
PRME Risk
Great
  • Debt / Equity↓ 1.0
  • Debt / FCF↓ 0.2
  • Interest coverage↑ 999.0

Prime Medicine stock volatility is higher than the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗